CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
You may also be interested in...
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.
US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.